Regencell Bioscience Holdings Limited (RGC) Key Metrics
RGC key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsRGC valuation Price multiples at each fiscal year-end price.
RGC returns How much profit the business earns on the capital it uses.
RGC per-share figures Results divided by the shares outstanding at year-end.
RGC financial health Debt, liquidity and how easily interest is covered.
RGC valuation history
RGC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RGC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RGC cash returned to shareholders
RGC price vs earnings per share
RGC key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.01B | $8.43B | $43.7M | $299.8M | $450.3M | — | — | — | — | — |
| Enterprise value | $3.00B | $8.42B | $35.8M | $288.7M | $434.7M | — | — | — | — | — |
| Price / book | 225.6 | — | 5.3 | 24.9 | 26.4 | — | — | — | — | — |
| Earnings yield | −0.4% | −0.0% | −9.8% | −2.0% | −1.6% | — | — | — | — | — |
| Free cash flow yield | −0.3% | −0.0% | −9.2% | −1.7% | −1.3% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.1% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $6.09 | $17.04 | $0.09 | $0.61 | $0.91 | — | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Earnings per share | −$0.02 | −$0.01 | −$0.01 | −$0.01 | −$0.02 | −$0.00 | −$0.00 | −$0.00 | — | — |
| Operating cash flow per share | −$0.02 | −$0.01 | −$0.01 | −$0.01 | −$0.01 | −$0.00 | −$0.00 | −$0.00 | — | — |
| Free cash flow per share | −$0.02 | −$0.01 | −$0.01 | −$0.01 | −$0.01 | −$0.00 | −$0.00 | −$0.00 | — | — |
| Cash per share | $0.03 | $0.01 | $0.02 | $0.02 | $0.03 | $0.00 | $0.00 | $0.00 | — | — |
| Book value per share | $0.03 | $0.01 | $0.02 | $0.02 | $0.03 | −$0.01 | −$0.01 | −$0.00 | — | — |
| Tangible book value per share | $0.03 | $0.01 | $0.02 | $0.02 | $0.03 | −$0.01 | −$0.01 | −$0.00 | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Debt per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.01 | $0.00 | — | — |
| Shares outstanding | 494.6M | 494.5M | 494.5M | 494.5M | 494.5M | 480.4M | 480.4M | 480.4M | — | — |
| Change in shares outstanding | +0.0% | 0.0% | 0.0% | 0.0% | +2.9% | 0.0% | 0.0% | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −128.5% | −54.8% | −42.5% | −40.4% | −113.6% | — | — | — | — | — |
| Return on invested capital (ROIC) | — | −700.0% | −588.2% | −422.0% | — | — | — | — | 11.8% | 18.1% |
| Return on assets (ROA) | −114.2% | −50.5% | −40.9% | −38.3% | −80.9% | −315.3% | −214.5% | −0.0% | 4.1% | 6.5% |
| Return on tangible assets | −79.4% | −62.3% | −51.0% | −46.5% | −41.2% | −395.9% | −158.0% | −160.7% | 4.6% | 7.5% |
| Free cash flow margin | — | — | — | — | — | — | — | — | 5.0% | 6.1% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | — | 3.65 | 2.41 |
| Financial health | ||||||||||
| Total debt | $295,811 | $544,415 | $85,741 | $463,669 | $771,255 | $3.7M | $3.1M | $2.1M | $2.37B | $2.22B |
| Cash & short-term investments | $14.2M | $4.9M | $8.0M | $11.6M | $16.4M | $59,413 | $386,979 | $243,307 | $228.8M | $246.5M |
| Net debt | −$13.9M | −$4.4M | −$7.9M | −$11.1M | −$15.6M | $3.6M | $2.7M | $1.8M | $2.14B | $1.98B |
| Debt / equity | 0.02 | 0.11 | 0.01 | 0.04 | 0.05 | — | — | — | — | — |
| Debt / assets | 0.02 | 0.09 | 0.01 | 0.04 | 0.04 | 10.83 | 5.97 | 8.56 | 0.83 | 0.84 |
| Net debt / EBITDA | — | — | — | — | — | — | — | — | 4.56 | 3.86 |
| Current ratio | 10.77 | 7.39 | 41.92 | 19.15 | 28.46 | 0.02 | 0.12 | 0.12 | 0.83 | 0.88 |
| Quick ratio | 10.77 | 7.39 | 42.71 | 19.24 | 28.51 | 0.02 | 0.12 | 0.12 | 0.78 | 0.84 |
| Interest coverage | — | — | — | — | -328.1 | — | — | — | — | — |
| Working capital | $12.9M | $4.2M | $7.9M | $11.0M | $15.9M | −$4.3M | −$2.8M | −$1.8M | −$98.1M | −$63.1M |
| Invested capital | −$547,279 | $507,674 | $343,205 | $929,207 | $1.4M | −$375,081 | $32,039 | $0 | $1.28B | $1.14B |
| Tangible asset value | $13.3M | $4.9M | $8.2M | $12.0M | $17.1M | −$4.0M | −$2.7M | −$1.8M | −$1.25B | −$1.21B |
| Net current asset value | $12.8M | $4.0M | $7.9M | $11.0M | $15.5M | −$4.3M | −$2.8M | −$1.8M | −$3.24B | −$3.04B |
| Graham net-net per share | $0.03 | $0.01 | $0.02 | $0.02 | $0.03 | −$0.01 | −$0.01 | −$0.00 | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $138.9M | $138.9M |
| Share buybacks (net) | $1.8M | — | — | — | — | — | — | — | $228.8M | — |
| Dividend payout ratio | — | — | — | — | — | — | — | — | 123.7% | 81.5% |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | 230.5% | 71.0% |
| Capex / revenue | — | — | — | — | — | — | — | — | 7.9% | 6.7% |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | 61.1% | 52.4% |
| Capex / depreciation | 0.00 | 0.39 | 0.01 | 0.04 | 1.29 | 0.00 | 12.38 | 12.38 | 0.98 | 0.93 |
| Stock-based compensation / revenue | — | — | — | — | — | — | — | — | 0.3% | 0.3% |
| SG&A / revenue | — | — | — | — | — | — | — | — | 2.7% | 16.0% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | — | 19.6 | 17.6 |
| Days of inventory on hand | — | — | -51.2 | -20.0 | -10.6 | -102.6 | — | — | 65.0 | 6.4 |
| Days payables outstanding | — | — | — | — | — | — | — | — | 633.6 | 63.1 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | -549.0 | -39.1 |
| Receivables turnover | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 18.66 | 20.75 |
| Payables turnover | — | — | — | — | — | — | — | — | 0.58 | 5.78 |
| Inventory turnover | — | — | — | — | — | — | — | — | 5.62 | 56.67 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.15 | 1.21 |
| Average receivables | — | — | $104,663 | $42,073 | $17,517 | $7,436 | — | — | $169.6M | $154.1M |
| Average payables | — | — | — | — | — | — | — | — | $213.5M | $212.2M |
| Average inventory | — | — | −$104,663 | −$42,073 | −$17,517 | −$7,436 | — | — | $21.9M | $21.6M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 13.7% | 14.1% |
Computed from RGC's annual financial statements (latest annual report filed October 7, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RGC valuation and financial ratios
Regencell Bioscience earned a return on equity of −128.5% in fiscal 2026. It ended the year with $0.3 million of debt and $14.2 million in cash and short-term investments, a net cash position of $13.9 million. It returned $1.8 million to shareholders: $0 in dividends and $1.8 million in share buybacks.
See the RGC income statement, the RGC chart for price history, or the RGC stock overview for the latest quote and news.
RGC key metrics FAQ
What is Regencell Bioscience's return on equity?
Regencell Bioscience's return on equity (ROE) was −128.5% in fiscal 2026: net income of -$11.7 million on average shareholders' equity of $9.1 million.
How much debt does Regencell Bioscience have?
Regencell Bioscience had total debt of $0.3 million at the end of fiscal 2026, a debt-to-equity ratio of 0.02 and more cash than debt.
Does Regencell Bioscience buy back its shares?
Yes. Regencell Bioscience spent $1.8 million on net share repurchases in fiscal 2026 Shares outstanding changed +0.0% over the year, to 494.6M..
What is Regencell Bioscience's free cash flow yield?
Regencell Bioscience generated -$7.7 million of free cash flow in fiscal 2026, a free cash flow yield of −0.3% on its market value at year-end ($3.0 billion).
What is Regencell Bioscience's current ratio?
Regencell Bioscience's current ratio was 10.77 at the end of fiscal 2026: current assets were 10.77 times current liabilities.